Evidence map›Paper›PMID 41206314›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026

Piperine alleviates retinal ischemic injury by mediating the APE1 signaling.

Qianxiong He, Yannan Chen, Peiwen Chen, Yi Wang, Rong Zou, Feng Zhao, Guangqun Zeng, Lin Zhang, Haiping Liu, Yuanjiang Shi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Qianxiong HeDepartment of Ophthalmology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, Sichuan Province, China; School of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, Sichuan Province, China.
Yannan ChenDepartment of Ophthalmology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, Sichuan Province, China; School of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, Sichuan Province, China.
Peiwen ChenDepartment of Ophthalmology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, Sichuan Province, China; School of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, Sichuan Province, China.
Yi WangSchool of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, Sichuan Province, China.
Rong ZouSchool of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, Sichuan Province, China.
Feng ZhaoDepartment of Health Laboratory Technology, School of Public Health, Chongqing Medical University, Chongqing 400016, China.
Guangqun ZengDepartment of Clinical Laboratory, People's Hospital of Pengzhou City, Pengzhou 611930, Sichuan Province, China.
Lin ZhangSchool of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, Sichuan Province, China.
Haiping LiuDepartment of Ophthalmology, Qinghai Provincial Hospital of Traditional Chinese Medicine, Xining 810000, Qinghai Province, China.
Yuanjiang ShiDepartment of Ophthalmology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, Sichuan Province, China; Southwest Medical University, Luzhou 646099, Sichuan Province, China.
Liuyi XiaoDepartment of Ophthalmology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, Sichuan Province, China.
Xiaorong XinDepartment of Ophthalmology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, Sichuan Province, China. Electronic address: xrgc19@uestc.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ischemic retinal damage is the most common cause of severe vision impairment and blindness. Anti-vascular endothelial growth factor (anti-VEGF) agents have transformed the treatment of retinal ischemic disorders and have become the cornerstone therapy for these conditions. Nonetheless, the risk for systemic and ocular adverse effects necessitates careful consideration. Meanwhile, the therapeutic potential of natural compounds for ischemic retinal injury is increasingly attracting attention. In this study, piperine (PIP), a natural compound derived from pepper, was found to reduce apoptosis by reducing the severity of retinal and optic nerve ischemic damage. However, the precise pharmacological mechanisms of PIP are yet to be fully elucidated. Molecular docking (MD) studies, MD simulations, and surface plasmon resonance experiments were conducted to determine the molecular targets of PIP. Our data revealed that PIP can bind to apurinic/apyrimidinic endonuclease 1 (APE1), thereby inhibiting apoptosis by decreasing the expression of caspase-9 and caspase-3 and regulating the mitochondrial pathway. In summary, PIP may directly targets the APE1 protein and further regulates the caspase-9/caspase-3 axis to provide neuroprotection against ischemic retinal injury.

Indexed as

AlkaloidsBenzodioxolesIschemiaNeuroprotective AgentsPiperidinesPolyunsaturated AlkamidesRetinal DiseasesSignal TransductionAnimalsApoptosisMaleMiceMolecular Docking SimulationRetinaAlkaloidsBenzodioxolesNeuroprotective AgentsPiperidinespiperinePolyunsaturated AlkamidesAPE1 signalingPiperineRetinal ischemic

Identifiers

PMID41206314
PMCPMC12976503

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.